Novel MRI-guided focussed ultrasound stimulated microbubble radiation enhancement treatment for breast cancer.

Autor: Dasgupta A; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Canada.; Physical Sciences, Sunnybrook Research Institute, Toronto, Canada., Saifuddin M; Physical Sciences, Sunnybrook Research Institute, Toronto, Canada., McNabb E; Physical Sciences, Sunnybrook Research Institute, Toronto, Canada., Ho L; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada., Lu L; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada., Vesprini D; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Karam I; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Soliman H; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Chow E; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Gandhi S; Department of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada.; Department of Medicine, University of Toronto, Toronto, Canada., Trudeau M; Department of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada.; Department of Medicine, University of Toronto, Toronto, Canada., Tran W; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Curpen B; Department of Medical Imaging, Sunnybrook Health Sciences, Toronto, Canada.; Department of Medical Imaging, University of Toronto, Toronto, Canada., Stanisz G; Physical Sciences, Sunnybrook Research Institute, Toronto, Canada.; Department of Biophysics, University of Toronto, Toronto, Canada.; Canada Research Chair in Cancer Imaging, Canadian Institutes of Health Research, Toronto, Canada., Sahgal A; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Canada., Kolios M; Ryerson University, Toronto, Canada., Czarnota GJ; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, T2, Toronto, ON, M4N3M5, Canada. gregoryczarnota.submissions@gmail.com.; Department of Radiation Oncology, University of Toronto, Toronto, Canada. gregoryczarnota.submissions@gmail.com.; Physical Sciences, Sunnybrook Research Institute, Toronto, Canada. gregoryczarnota.submissions@gmail.com.; Department of Biophysics, University of Toronto, Toronto, Canada. gregoryczarnota.submissions@gmail.com.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Aug 21; Vol. 13 (1), pp. 13566. Date of Electronic Publication: 2023 Aug 21.
DOI: 10.1038/s41598-023-40551-5
Abstrakt: Preclinical studies have demonstrated focused ultrasound (FUS) stimulated microbubble (MB) rupture leads to the activation of acid sphingomyelinase-ceramide pathway in the endothelial cells. When radiotherapy (RT) is delivered concurrently with FUS-MB, apoptotic pathway leads to increased cell death resulting in potent radiosensitization. Here we report the first human trial of using magnetic resonance imaging (MRI) guided FUS-MB treatment in the treatment of breast malignancies. In the phase 1 prospective interventional study, patients with breast cancer were treated with fractionated RT (5 or 10 fractions) to the disease involving breast or chest wall. FUS-MB treatment was delivered before 1st and 5th fractions of RT (within 1 h). Eight patients with 9 tumours were treated. All 7 evaluable patients with at least 3 months follow-up treated for 8 tumours had a complete response in the treated site. The maximum acute toxicity observed was grade 2 dermatitis in 1 site, and grade 1 in 8 treated sites, at one month post RT, which recovered at 3 months. No RT-related late effect or FUS-MB related toxicity was noted. This study demonstrated safety of combined FUS-MB and RT treatment. Promising response rates suggest potential strong radiosensitization effects of the investigational modality.Trial registration: clinicaltrials.gov, identifier NCT04431674.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje